| Company Name: |
Guangzhou Younan Technology Co., Ltd
|
| Tel: |
020-82000279 18988968278 |
| Email: |
YN_research@163.com |
| Products Intro: |
Product Name:TAK-418
CAS:1818252-53-7
Purity:0.98 Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:5-((1R,2R)-2-((Cyclopropylmethyl)amino)cyclopropyl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide hydrochloride
CAS:1818252-53-7
Purity:98% Package:5mg;10mg;25mg;50mg;100mg;250mg Remarks:BD01476004
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:TAK-418
CAS:1818252-53-7
Purity:98.87% Package:1mg/RMB 2660;5mg/RMB 5820;10mg/RMB 7860
|
TAK-418 manufacturers
- TAK-418
-
- $140.00 / 1mg
-
2025-11-10
- CAS:1818252-53-7
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
|
| | TAK-418 Basic information |
| Product Name: | TAK-418 | | Synonyms: | TAK-418;5-((1R,2R)-2-((Cyclopropylmethyl)amino)cyclopropyl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide hydrochloride;3-Thiophenecarboxamide, 5-[(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl]-N-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1);TAK-418, 10 mM in DMSO | | CAS: | 1818252-53-7 | | MF: | | | MW: | 356.91 | | EINECS: | | | Product Categories: | | | Mol File: | 1818252-53-7.mol |  |
| | TAK-418 Chemical Properties |
| storage temp. | Store at -20°C, sealed storage, away from moisture and light | | form | Solid-Liquid Mixture | | color | White to yellow |
| | TAK-418 Usage And Synthesis |
| Uses | TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models[1][2]. | | in vivo | TAK-418 (1 mg/kg; p.o.; once daily for 14 days) ameliorates some autism spectrum disorder (ASD) -like behaviors in neurodevelopmental disorder model rodents[1].
TAK-418 increases H3K4me1/2/3 and H3K9me2 levels at the Ucp2 gene and induced Ucp2mRNA expression in primary cultured rat neurons. TAK-418 also increases H3K4me1/2/3 at the Bdnf gene. TAK-418 avoids the steric interference with GFI1B in the binding pocket through the generation of a compact formylated adduct form of coenzyme flavin adenine dinucleotide (FAD). TAK-418 shows a good pharmacokinetic profile in rodents and inhibits LSD1 enzyme activity in the brain without causing hematological toxicity in rodents[1].
Single administration of TAK-418 at 1 or 3 mg/kg increases H3K4me2 levels at Ucp2 gene in the mouse brain[1].
TAK-418 can ameliorate neurological problems at the cellular, molecular, gene expression, and functional levels in a mouse model of KS (Kmt2d+/βGeo mice)[2]. | | IC 50 | KDM1/LSD1 | | References | [1] Baba R, et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv. 2021;7(11):eaba1187. Published 2021 Mar 12. DOI:10.1126/sciadv.aba1187
[2] Zhang L, et al. Inhibition of KDM1A activity restores adult neurogenesis and improves hippocampal memory in a mouse model of Kabuki syndrome. Mol Ther Methods Clin Dev. 2021;20:779-791. Published 2021 Feb 18 DOI:10.1016/j.omtm.2021.02.011 |
| | TAK-418 Preparation Products And Raw materials |
|